10/120
0.4 / 5 stars
All 120 Win/Lose results shown below
MNOV Roast Me summary
MEDICINOVA INC (MNOV). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseMNOV / S&P -3.65% / 15.20% |
LoseMNOV / S&P MNOV unavailable / 15.00% |
LoseMNOV / S&P MNOV unavailable / 50.40% |
| 2026-Q11/3 |
WinMNOV / S&P 4.58% / -4.33% |
LoseMNOV / S&P MNOV unavailable / 11.30% |
LoseMNOV / S&P MNOV unavailable / 27.70% |
| 2025-Q41/3 |
WinMNOV / S&P 3.15% / 2.65% |
LoseMNOV / S&P MNOV unavailable / 9.00% |
LoseMNOV / S&P MNOV unavailable / 13.40% |
| 2025-Q30/3 |
LoseMNOV / S&P -3.05% / 8.12% |
LoseMNOV / S&P MNOV unavailable / 4.61% |
LoseMNOV / S&P MNOV unavailable / 13.45% |
| 2025-Q20/3 |
LoseMNOV / S&P -10.27% / 10.94% |
LoseMNOV / S&P MNOV unavailable / 4.83% |
LoseMNOV / S&P MNOV unavailable / 10.63% |
| 2025-Q10/3 |
LoseMNOV / S&P -30.48% / -4.27% |
LoseMNOV / S&P MNOV unavailable / 4.98% |
LoseMNOV / S&P MNOV unavailable / 10.57% |
| 2024-Q40/3 |
LoseMNOV / S&P 0.00% / 2.41% |
LoseMNOV / S&P MNOV unavailable / 5.25% |
LoseMNOV / S&P MNOV unavailable / 6.15% |
| 2024-Q31/3 |
WinMNOV / S&P 45.83% / 5.89% |
LoseMNOV / S&P MNOV unavailable / 5.89% |
LoseMNOV / S&P MNOV unavailable / 6.11% |
| 2024-Q20/3 |
LoseMNOV / S&P -0.69% / 4.28% |
LoseMNOV / S&P MNOV unavailable / 5.38% |
LoseMNOV / S&P MNOV unavailable / 5.12% |
| 2024-Q10/3 |
LoseMNOV / S&P -3.33% / 10.56% |
LoseMNOV / S&P MNOV unavailable / 5.71% |
LoseMNOV / S&P MNOV unavailable / 5.59% |
| 2023-Q40/3 |
LoseMNOV / S&P -28.23% / 11.69% |
LoseMNOV / S&P MNOV unavailable / 6.81% |
LoseMNOV / S&P MNOV unavailable / 7.78% |
| 2023-Q30/3 |
LoseMNOV / S&P -9.13% / -3.27% |
LoseMNOV / S&P MNOV unavailable / 7.52% |
LoseMNOV / S&P MNOV unavailable / -5.03% |
| 2023-Q20/3 |
LoseMNOV / S&P 6.48% / 8.74% |
LoseMNOV / S&P MNOV unavailable / 9.50% |
LoseMNOV / S&P MNOV unavailable / -8.57% |
| 2023-Q10/3 |
LoseMNOV / S&P 5.37% / 7.50% |
LoseMNOV / S&P MNOV unavailable / 10.77% |
LoseMNOV / S&P MNOV unavailable / -15.69% |
| 2022-Q40/3 |
LoseMNOV / S&P -5.53% / 7.56% |
LoseMNOV / S&P MNOV unavailable / 11.88% |
LoseMNOV / S&P MNOV unavailable / -17.99% |
| 2022-Q30/3 |
LoseMNOV / S&P -14.23% / -4.88% |
LoseMNOV / S&P MNOV unavailable / 13.47% |
LoseMNOV / S&P MNOV unavailable / -1.41% |
| 2022-Q21/3 |
WinMNOV / S&P -5.24% / -16.10% |
LoseMNOV / S&P MNOV unavailable / 13.71% |
LoseMNOV / S&P MNOV unavailable / 11.04% |
| 2022-Q11/3 |
WinMNOV / S&P -0.37% / -4.60% |
LoseMNOV / S&P MNOV unavailable / 15.97% |
LoseMNOV / S&P MNOV unavailable / 42.23% |
| 2021-Q40/3 |
LoseMNOV / S&P -29.29% / 11.03% |
LoseMNOV / S&P MNOV unavailable / 15.00% |
LoseMNOV / S&P MNOV unavailable / 96.40% |
| 2021-Q30/3 |
LoseMNOV / S&P -10.82% / 0.58% |
LoseMNOV / S&P MNOV unavailable / 10.77% |
LoseMNOV / S&P MNOV unavailable / 69.42% |
| 2021-Q20/3 |
LoseMNOV / S&P -15.84% / 8.55% |
LoseMNOV / S&P MNOV unavailable / 6.58% |
LoseMNOV / S&P MNOV unavailable / 51.81% |
| 2021-Q10/3 |
LoseMNOV / S&P -3.99% / 6.17% |
LoseMNOV / S&P MNOV unavailable / -1.06% |
LoseMNOV / S&P MNOV unavailable / 7.39% |
| 2020-Q40/3 |
LoseMNOV / S&P 0.38% / 12.15% |
LoseMNOV / S&P MNOV unavailable / -3.72% |
LoseMNOV / S&P MNOV unavailable / -33.42% |
| 2020-Q30/3 |
LoseMNOV / S&P -3.32% / 8.93% |
LoseMNOV / S&P MNOV unavailable / -2.04% |
LoseMNOV / S&P MNOV unavailable / -27.10% |
| 2020-Q21/3 |
WinMNOV / S&P 45.70% / 20.54% |
LoseMNOV / S&P MNOV unavailable / -0.46% |
LoseMNOV / S&P MNOV unavailable / -27.11% |
| 2020-Q10/3 |
LoseMNOV / S&P -44.81% / -19.60% |
LoseMNOV / S&P MNOV unavailable / 3.47% |
LoseMNOV / S&P MNOV unavailable / -14.75% |
| 2019-Q40/3 |
LoseMNOV / S&P -15.33% / 9.07% |
LoseMNOV / S&P MNOV unavailable / 5.36% |
LoseMNOV / S&P MNOV unavailable / 2.99% |
| 2019-Q30/3 |
LoseMNOV / S&P -17.34% / 1.70% |
LoseMNOV / S&P MNOV unavailable / 5.02% |
LoseMNOV / S&P MNOV unavailable / 0.21% |
| 2019-Q21/3 |
WinMNOV / S&P 16.30% / 4.30% |
LoseMNOV / S&P MNOV unavailable / 6.64% |
LoseMNOV / S&P MNOV unavailable / 8.65% |
| 2019-Q10/3 |
LoseMNOV / S&P 1.35% / 13.65% |
LoseMNOV / S&P MNOV unavailable / 8.12% |
LoseMNOV / S&P MNOV unavailable / 14.29% |
| 2018-Q40/3 |
LoseMNOV / S&P -34.59% / -13.52% |
LoseMNOV / S&P MNOV unavailable / 9.05% |
LoseMNOV / S&P MNOV unavailable / 18.23% |
| 2018-Q31/3 |
WinMNOV / S&P 56.91% / 7.71% |
LoseMNOV / S&P MNOV unavailable / 10.21% |
LoseMNOV / S&P MNOV unavailable / 19.06% |
| 2018-Q20/3 |
LoseMNOV / S&P -22.11% / 3.43% |
LoseMNOV / S&P MNOV unavailable / 9.03% |
LoseMNOV / S&P MNOV unavailable / 14.46% |
| 2018-Q11/3 |
WinMNOV / S&P 57.96% / -0.76% |
LoseMNOV / S&P MNOV unavailable / 7.68% |
LoseMNOV / S&P MNOV unavailable / 12.46% |
| 2017-Q40/3 |
LoseMNOV / S&P 1.57% / 6.64% |
LoseMNOV / S&P MNOV unavailable / 7.03% |
LoseMNOV / S&P MNOV unavailable / 13.82% |
| 2017-Q31/3 |
WinMNOV / S&P 21.10% / 4.48% |
LoseMNOV / S&P MNOV unavailable / 5.68% |
LoseMNOV / S&P MNOV unavailable / 17.57% |
| 2017-Q20/3 |
LoseMNOV / S&P -12.19% / 3.09% |
LoseMNOV / S&P MNOV unavailable / 4.83% |
LoseMNOV / S&P MNOV unavailable / 17.74% |
| 2017-Q10/3 |
LoseMNOV / S&P -0.66% / 6.07% |
LoseMNOV / S&P MNOV unavailable / 3.67% |
LoseMNOV / S&P MNOV unavailable / 13.32% |
| 2016-Q40/3 |
LoseMNOV / S&P -19.49% / 3.82% |
LoseMNOV / S&P MNOV unavailable / 2.09% |
LoseMNOV / S&P MNOV unavailable / 7.05% |
| 2016-Q30/3 |
LoseMNOV / S&P -0.79% / 3.85% |
LoseMNOV / S&P MNOV unavailable / 0.20% |
LoseMNOV / S&P MNOV unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | MNOV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 9.16% | 20.78% |
| Annualized return | 9.16% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | MNOV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -65.38% | 83.14% |
| Annualized return | -19.11% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | MNOV total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -75.80% | 319.30% |
| Annualized return | -13.23% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |